Research ArticleArticle
Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Cotransporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance, and Ketoconazole Interaction Studies
James F. Sigafoos, Gary D. Bowers, Stephen Castellino, Amanda G. Culp, David S. Wagner, Melinda J. Reese, Joan E. Humphreys, Elizabeth K. Hussey, Robin L. O'Connor Semmes, Anita Kapur, Wenli Tao, Robert L. Dobbins and Joseph W. Polli
Drug Metabolism and Disposition November 2012, 40 (11) 2090-2101; DOI: https://doi.org/10.1124/dmd.112.047258
James F. Sigafoos
Departments of Drug Metabolism and Pharmacokinetics (J.F.S., G.D.B., S.C., A.G.C., D.S.W., M.J.R., J.E.H., J.W.P.) and Clinical Pharmacology (E.K.H., R.L.O.S., A.K., W.T., R.L.D.), GlaxoSmithKline, Research Triangle Park, North Carolina
Gary D. Bowers
Departments of Drug Metabolism and Pharmacokinetics (J.F.S., G.D.B., S.C., A.G.C., D.S.W., M.J.R., J.E.H., J.W.P.) and Clinical Pharmacology (E.K.H., R.L.O.S., A.K., W.T., R.L.D.), GlaxoSmithKline, Research Triangle Park, North Carolina
Stephen Castellino
Departments of Drug Metabolism and Pharmacokinetics (J.F.S., G.D.B., S.C., A.G.C., D.S.W., M.J.R., J.E.H., J.W.P.) and Clinical Pharmacology (E.K.H., R.L.O.S., A.K., W.T., R.L.D.), GlaxoSmithKline, Research Triangle Park, North Carolina
Amanda G. Culp
Departments of Drug Metabolism and Pharmacokinetics (J.F.S., G.D.B., S.C., A.G.C., D.S.W., M.J.R., J.E.H., J.W.P.) and Clinical Pharmacology (E.K.H., R.L.O.S., A.K., W.T., R.L.D.), GlaxoSmithKline, Research Triangle Park, North Carolina
David S. Wagner
Departments of Drug Metabolism and Pharmacokinetics (J.F.S., G.D.B., S.C., A.G.C., D.S.W., M.J.R., J.E.H., J.W.P.) and Clinical Pharmacology (E.K.H., R.L.O.S., A.K., W.T., R.L.D.), GlaxoSmithKline, Research Triangle Park, North Carolina
Melinda J. Reese
Departments of Drug Metabolism and Pharmacokinetics (J.F.S., G.D.B., S.C., A.G.C., D.S.W., M.J.R., J.E.H., J.W.P.) and Clinical Pharmacology (E.K.H., R.L.O.S., A.K., W.T., R.L.D.), GlaxoSmithKline, Research Triangle Park, North Carolina
Joan E. Humphreys
Departments of Drug Metabolism and Pharmacokinetics (J.F.S., G.D.B., S.C., A.G.C., D.S.W., M.J.R., J.E.H., J.W.P.) and Clinical Pharmacology (E.K.H., R.L.O.S., A.K., W.T., R.L.D.), GlaxoSmithKline, Research Triangle Park, North Carolina
Elizabeth K. Hussey
Departments of Drug Metabolism and Pharmacokinetics (J.F.S., G.D.B., S.C., A.G.C., D.S.W., M.J.R., J.E.H., J.W.P.) and Clinical Pharmacology (E.K.H., R.L.O.S., A.K., W.T., R.L.D.), GlaxoSmithKline, Research Triangle Park, North Carolina
Robin L. O'Connor Semmes
Departments of Drug Metabolism and Pharmacokinetics (J.F.S., G.D.B., S.C., A.G.C., D.S.W., M.J.R., J.E.H., J.W.P.) and Clinical Pharmacology (E.K.H., R.L.O.S., A.K., W.T., R.L.D.), GlaxoSmithKline, Research Triangle Park, North Carolina
Anita Kapur
Departments of Drug Metabolism and Pharmacokinetics (J.F.S., G.D.B., S.C., A.G.C., D.S.W., M.J.R., J.E.H., J.W.P.) and Clinical Pharmacology (E.K.H., R.L.O.S., A.K., W.T., R.L.D.), GlaxoSmithKline, Research Triangle Park, North Carolina
Wenli Tao
Departments of Drug Metabolism and Pharmacokinetics (J.F.S., G.D.B., S.C., A.G.C., D.S.W., M.J.R., J.E.H., J.W.P.) and Clinical Pharmacology (E.K.H., R.L.O.S., A.K., W.T., R.L.D.), GlaxoSmithKline, Research Triangle Park, North Carolina
Robert L. Dobbins
Departments of Drug Metabolism and Pharmacokinetics (J.F.S., G.D.B., S.C., A.G.C., D.S.W., M.J.R., J.E.H., J.W.P.) and Clinical Pharmacology (E.K.H., R.L.O.S., A.K., W.T., R.L.D.), GlaxoSmithKline, Research Triangle Park, North Carolina
Joseph W. Polli
Departments of Drug Metabolism and Pharmacokinetics (J.F.S., G.D.B., S.C., A.G.C., D.S.W., M.J.R., J.E.H., J.W.P.) and Clinical Pharmacology (E.K.H., R.L.O.S., A.K., W.T., R.L.D.), GlaxoSmithKline, Research Triangle Park, North Carolina
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
DISPOSITION AND DRUG INTERACTION RISK OF REMOGLIFLOZIN
James F. Sigafoos, Gary D. Bowers, Stephen Castellino, Amanda G. Culp, David S. Wagner, Melinda J. Reese, Joan E. Humphreys, Elizabeth K. Hussey, Robin L. O'Connor Semmes, Anita Kapur, Wenli Tao, Robert L. Dobbins and Joseph W. Polli
Drug Metabolism and Disposition November 1, 2012, 40 (11) 2090-2101; DOI: https://doi.org/10.1124/dmd.112.047258
Research ArticleArticle
DISPOSITION AND DRUG INTERACTION RISK OF REMOGLIFLOZIN
James F. Sigafoos, Gary D. Bowers, Stephen Castellino, Amanda G. Culp, David S. Wagner, Melinda J. Reese, Joan E. Humphreys, Elizabeth K. Hussey, Robin L. O'Connor Semmes, Anita Kapur, Wenli Tao, Robert L. Dobbins and Joseph W. Polli
Drug Metabolism and Disposition November 1, 2012, 40 (11) 2090-2101; DOI: https://doi.org/10.1124/dmd.112.047258
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement